Ind-Swift Laboratories Ltd

Ind-Swift Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Ind-Swift Laboratories Ltd

₹ 94.1 1.79%
09 Jun 10:39 a.m.
indswiftlabs.com BSE: 532305 NSE: INDSWFTLAB
About

Incorporated in 1995, Ind-Swift Laboratories Ltd is in the business of Bulk Drugs & Pharmaceuticals[1]

Key Points

Business Overview:[1]
ISLL is a global manufacture of APIs, Intermediates and formulation (through group collaboration). It caters to the API needs of regulated markets including USFDA, EDQM, PMDA, ANVISA, EU-GMP, KFDA, NMO, ANSM, Cofepris, TGA, WHO, ROW. ISLL is present in all stages of drug substance/product including new chemical/molecular research to formulation development.
Company manufactures APIs towards Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. It also holds global leadership positions in the Macrolide Antibiotic segment.

Website BSE NSE
  • Market Cap ₹ 570 Cr.
  • Current Price ₹ 94.1
  • High / Low ₹ 186 / 67.2
  • Stock P/E 6.36
  • Book Value ₹ 171
  • Dividend Yield 0.00 %
  • ROCE 19.7 %
  • ROE 17.3 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Stock is trading at 0.55 times its book value
  • Company has delivered good profit growth of 47.8% CAGR over last 5 years
  • Debtor days have improved from 113 to 31.7 days.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -1.06%
  • The company has delivered a poor sales growth of 11.1% over past five years.
  • Company has a low return on equity of 9.15% over last 3 years.
  • Contingent liabilities of Rs.465 Cr.
  • Earnings include an other income of Rs.450 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
240.30 275.82 271.52 287.55 302.41 270.30 299.01 270.30 276.28 381.73 30.46 2.71 1.41
186.89 240.74 218.53 230.70 246.50 206.90 239.20 206.90 222.04 309.22 34.99 14.71 10.23
Operating Profit 53.41 35.08 52.99 56.85 55.91 63.40 59.81 63.40 54.24 72.51 -4.53 -12.00 -8.82
OPM % 22.23% 12.72% 19.52% 19.77% 18.49% 23.46% 20.00% 23.46% 19.63% 19.00% -14.87% -442.80% -625.53%
6.45 20.63 7.39 7.54 8.36 7.40 5.55 7.40 7.11 411.84 11.14 12.95 13.81
Interest 23.73 23.49 23.98 23.98 22.38 21.14 20.38 21.14 21.05 -11.48 0.17 0.41 0.11
Depreciation 21.26 81.78 16.26 16.39 15.42 13.19 13.89 13.19 13.56 12.67 0.25 0.22 0.25
Profit before tax 14.87 -49.56 20.14 24.02 26.47 36.47 31.09 36.47 26.74 483.16 6.19 0.32 4.63
Tax % 0.00% 27.48% 0.00% 0.00% -10.43% 17.49% 45.19% 17.49% 19.04% 27.65% 0.00% 0.00% 0.00%
14.87 -63.19 20.14 24.02 29.22 30.10 17.05 30.10 21.65 349.59 6.19 0.32 4.64
EPS in Rs 2.52 -10.69 3.41 4.07 4.95 5.09 2.89 5.09 3.66 59.17 1.05 0.05 0.79
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
1,081 941 646 639 694 731 724 752 857 988 1,152 1,227 416
1,011 882 557 532 589 604 599 610 676 788 930 977 369
Operating Profit 70 59 89 107 105 127 125 142 180 200 222 250 47
OPM % 7% 6% 14% 17% 15% 17% 17% 19% 21% 20% 19% 20% 11%
4 -19 -31 1 15 16 130 36 23 34 7 432 450
Interest 140 117 117 106 88 28 92 107 100 96 92 51 -11
Depreciation 54 66 84 85 88 87 104 90 87 131 57 53 13
Profit before tax -120 -143 -143 -83 -56 29 59 -20 16 8 79 577 494
Tax % -1% -14% -17% -29% -29% 38% 35% 6% 127% 171% 46% 28%
-119 -123 -119 -59 -40 18 39 -21 -4 -6 42 418 361
EPS in Rs -30.30 -29.96 -29.09 -14.37 -8.88 3.89 8.11 -3.52 -0.74 -0.97 7.19 70.81 61.06
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 3%
5 Years: 11%
3 Years: 13%
TTM: -63%
Compounded Profit Growth
10 Years: 13%
5 Years: 48%
3 Years: 222%
TTM: -9%
Stock Price CAGR
10 Years: 13%
5 Years: 26%
3 Years: 17%
1 Year: -19%
Return on Equity
10 Years: 0%
5 Years: 5%
3 Years: 9%
Last Year: 17%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 39 41 42 42 45 46 48 60 60 60 60 59 59
Reserves 813 682 551 473 480 497 542 585 579 573 616 863 948
1,240 1,355 1,413 1,457 1,242 1,083 1,148 1,031 996 944 854 8 8
272 252 233 238 353 371 174 184 182 226 259 174 121
Total Liabilities 2,364 2,330 2,238 2,210 2,121 1,997 1,913 1,860 1,817 1,803 1,788 1,105 1,136
1,169 1,173 1,114 1,095 1,042 934 913 843 752 630 587 8 7
CWIP 161 78 115 82 70 69 20 11 19 10 8 0 0
Investments 27 27 26 26 26 26 26 26 55 111 85 166 247
1,006 1,052 983 1,007 982 968 953 979 991 1,052 1,108 931 882
Total Assets 2,364 2,330 2,238 2,210 2,121 1,997 1,913 1,860 1,817 1,803 1,788 1,105 1,136

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-46 0 100 80 93 71 -75 123 135 136 183 -180
-48 0 -37 -30 -31 -17 -2 -10 -10 3 -14 -104
66 0 -64 -48 -69 -62 100 -133 -124 -140 -168 700
Net Cash Flow -28 0 -0 3 -7 -8 23 -20 1 -1 1 416

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 133 166 212 205 179 191 168 187 171 158 149 32
Inventory Days 190 187 319 377 317 305 302 330 304 303 253 0
Days Payable 81 102 119 137 88 112 110 122 106 120 114
Cash Conversion Cycle 242 250 412 445 409 384 359 395 368 342 287 32
Working Capital Days 255 279 287 253 108 97 317 324 294 288 261 -16
ROCE % 2% 0% 1% 2% 2% 3% 4% 5% 7% 7% 13% 20%

Shareholding Pattern

Numbers in percentages

14 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
42.00% 42.01% 42.01% 42.01% 42.01% 42.01% 42.01% 42.01% 42.01% 42.01% 42.01% 40.94%
0.00% 0.00% 0.04% 0.00% 0.08% 0.17% 0.31% 0.26% 1.27% 0.65% 0.46% 3.07%
19.49% 19.49% 19.49% 19.49% 19.49% 19.49% 18.73% 8.03% 0.94% 0.94% 0.94% 0.91%
38.50% 38.51% 38.48% 38.52% 38.44% 38.34% 38.96% 49.72% 55.81% 56.41% 56.61% 55.08%
No. of Shareholders 24,91024,22624,45623,39722,96225,40524,63322,43925,46128,88328,75228,117

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Nov 2020
    Transcript
    Notes
    PPT
  • Jul 2020
    Transcript
    Notes
    PPT